[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201892443A1 - Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови - Google Patents

Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови

Info

Publication number
EA201892443A1
EA201892443A1 EA201892443A EA201892443A EA201892443A1 EA 201892443 A1 EA201892443 A1 EA 201892443A1 EA 201892443 A EA201892443 A EA 201892443A EA 201892443 A EA201892443 A EA 201892443A EA 201892443 A1 EA201892443 A1 EA 201892443A1
Authority
EA
Eurasian Patent Office
Prior art keywords
blood cells
antibodies against
pharmaceutical compositions
clinical use
against antigen
Prior art date
Application number
EA201892443A
Other languages
English (en)
Inventor
Марк Р. Х. Кребс
Дэвид Дай
Шантану Сьюл
Даниа Рабах
Дэвид Мартин
Original Assignee
Байоджен Ма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Ма Инк. filed Critical Байоджен Ма Инк.
Publication of EA201892443A1 publication Critical patent/EA201892443A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Предлагаются препараты и режимы дозирования антител против антигена 2 дендритных клеток крови (BDCA2). Эти препараты и режимы дозирования находят применение при лечении связанных с BDCA2 расстройств/заболеваний, таких как системная красная волчанка, кожная красная волчанка и дискоидная красная волчанка, а также синдром высвобождения цитокинов.
EA201892443A 2016-04-28 2017-04-27 Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови EA201892443A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Publications (1)

Publication Number Publication Date
EA201892443A1 true EA201892443A1 (ru) 2019-04-30

Family

ID=58672794

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892443A EA201892443A1 (ru) 2016-04-28 2017-04-27 Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови

Country Status (15)

Country Link
US (1) US20190284281A1 (ru)
EP (1) EP3448425A1 (ru)
JP (3) JP7045327B2 (ru)
KR (3) KR102366547B1 (ru)
CN (2) CN109475623B (ru)
AU (2) AU2017258191B2 (ru)
BR (1) BR112018072125A2 (ru)
CA (1) CA3022116A1 (ru)
CO (1) CO2018012506A2 (ru)
EA (1) EA201892443A1 (ru)
IL (1) IL262514A (ru)
MA (1) MA44763A (ru)
MX (2) MX2018012945A (ru)
PH (1) PH12018502278A1 (ru)
WO (1) WO2017189827A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040671A1 (en) * 2017-08-22 2019-02-28 Biogen Ma Inc. METHODS OF PURIFYING ANTIBODIES HAVING REDUCED AGGREGATES OF HIGH MOLECULAR WEIGHT
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
CN116963716A (zh) * 2020-12-03 2023-10-27 渤健马萨诸塞州股份有限公司 治疗皮肤型红斑狼疮和系统性红斑狼疮的方法
WO2023017936A1 (ko) 2021-08-09 2023-02-16 주식회사 인벤테라제약 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥(蘇州)有限公司 抗bdca2抗體及其用途
TW202432188A (zh) * 2022-12-28 2024-08-16 大陸商映恩生物製藥(蘇州)有限公司 抗bdca2抗體-藥物偶聯物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030579T2 (en) * 2003-04-04 2017-05-29 Genentech Inc High Concentration Antibody And Protein Products
DK2928923T3 (da) * 2012-12-10 2020-02-17 Biogen Ma Inc Antistoffer mod dendritisk celle-antigen 2 fra blod og anvendelser deraf

Also Published As

Publication number Publication date
CN109475623A (zh) 2019-03-15
AU2017258191B2 (en) 2024-06-13
CN116850282A (zh) 2023-10-10
MX2023008075A (es) 2023-07-18
JP7045327B2 (ja) 2022-03-31
CN109475623B (zh) 2023-05-26
KR20190002563A (ko) 2019-01-08
WO2017189827A1 (en) 2017-11-02
JP2019520316A (ja) 2019-07-18
CO2018012506A2 (es) 2018-12-14
AU2024203240A1 (en) 2024-06-13
CA3022116A1 (en) 2017-11-02
EP3448425A1 (en) 2019-03-06
JP2024038308A (ja) 2024-03-19
US20190284281A1 (en) 2019-09-19
PH12018502278A1 (en) 2019-09-09
KR20240033168A (ko) 2024-03-12
JP2022084782A (ja) 2022-06-07
BR112018072125A2 (pt) 2019-03-19
AU2017258191A1 (en) 2018-11-15
KR20220028150A (ko) 2022-03-08
IL262514A (en) 2018-12-31
MX2018012945A (es) 2019-03-06
KR102366547B1 (ko) 2022-02-23
MA44763A (fr) 2019-03-06

Similar Documents

Publication Publication Date Title
EA201892443A1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
CY1122060T1 (el) Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων
AR110645A1 (es) Anticuerpos anti-hla-g y uso de los mismos
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EP4406554A3 (en) Anti-cd3 antibody formulations
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201790239A1 (ru) Молекула-носитель для антигенов
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
EA202090063A1 (ru) Композиции и способы для лечения таупатий
CY1124922T1 (el) Καινοτομος σταθερη φαρμακοτεχνικη μορφη για αντισωματα fxia
BR112022001575A2 (pt) Formulações de anticorpos anti-pvrig e usos dos mesmos
EA201791067A1 (ru) Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса
BR112018069930A2 (pt) agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения